BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Brodsky RA. Complement in hemolytic anemia. Blood 2015;126:2459-65. [DOI: 10.1182/blood-2015-06-640995] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 7.9] [Reference Citation Analysis]
Number Citing Articles
1 Tanaka K, Adams B, Aris AM, Fujita N, Ogawa M, Ortiz S, Vallee M, Greenbaum LA. The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab. Pediatr Nephrol 2021;36:889-98. [PMID: 33048203 DOI: 10.1007/s00467-020-04774-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
2 Yao X, Verkman AS. Complement regulator CD59 prevents peripheral organ injury in rats made seropositive for neuromyelitis optica immunoglobulin G. Acta Neuropathol Commun 2017;5:57. [PMID: 28750658 DOI: 10.1186/s40478-017-0462-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
3 Gediz F, Payzin BK, Cakmak OZ, Uzum Y, Ernur D, Sahin F. Paroxysmal Nocturnal Hemoglobinuria in the Differential Diagnosis of Thrombocytopenia. Hematol Rep 2017;9:6862. [PMID: 28435653 DOI: 10.4081/hr.2017.6862] [Reference Citation Analysis]
4 Gavriilaki E, Brodsky RA. Complementopathies and precision medicine. J Clin Invest 2020;130:2152-63. [PMID: 32310222 DOI: 10.1172/JCI136094] [Cited by in Crossref: 36] [Cited by in F6Publishing: 20] [Article Influence: 36.0] [Reference Citation Analysis]
5 Lu P, Ma Y, Wei S, Liang X. The dual role of complement in cancers, from destroying tumors to promoting tumor development. Cytokine 2021;143:155522. [PMID: 33849765 DOI: 10.1016/j.cyto.2021.155522] [Reference Citation Analysis]
6 Fontaine MJ. Role of complement in patients with autoimmune hemolytic anemia and platelet transfusion refractoriness. Transfus Clin Biol 2019;26:152-4. [PMID: 31277985 DOI: 10.1016/j.tracli.2019.06.232] [Reference Citation Analysis]
7 Berkman SA, Song SS. Ischemic Stroke in the Young. Clin Appl Thromb Hemost 2021;27:10760296211002274. [PMID: 33870763 DOI: 10.1177/10760296211002274] [Reference Citation Analysis]
8 Mullins M, Jiang X, Bylsma LC, Fryzek JP, Reichert H, Chen EC, Kummar S, Rosenthal A. Cold agglutinin disease burden: a longitudinal analysis of anemia, medications, transfusions, and health care utilization. Blood Adv 2017;1:839-48. [PMID: 29296728 DOI: 10.1182/bloodadvances.2017004390] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
9 Raina R, Chauvin A, Fox K, Kesav N, Ascha M, Vachharajani TJ, Krishnappa V. Effect of Immunosuppressive Therapy on the Occurrence of Atypical Hemolytic Uremic Syndrome in Renal Transplant Recipients. Ann Transplant 2018;23:631-8. [PMID: 30190449 DOI: 10.12659/AOT.909781] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Harder MJ, Höchsmann B, Dopler A, Anliker M, Weinstock C, Skerra A, Simmet T, Schrezenmeier H, Schmidt CQ. Different Levels of Incomplete Terminal Pathway Inhibition by Eculizumab and the Clinical Response of PNH Patients. Front Immunol 2019;10:1639. [PMID: 31379839 DOI: 10.3389/fimmu.2019.01639] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
11 Vaught AJ, Braunstein EM, Jasem J, Yuan X, Makhlin I, Eloundou S, Baines AC, Merrill SA, Chaturvedi S, Blakemore K, Sperati CJ, Brodsky RA. Germline mutations in the alternative pathway of complement predispose to HELLP syndrome. JCI Insight 2018;3:99128. [PMID: 29563339 DOI: 10.1172/jci.insight.99128] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 11.5] [Reference Citation Analysis]
12 Sartain SE, Turner NA, Moake JL. Brain microvascular endothelial cells exhibit lower activation of the alternative complement pathway than glomerular microvascular endothelial cells. J Biol Chem 2018;293:7195-208. [PMID: 29555686 DOI: 10.1074/jbc.RA118.002639] [Cited by in Crossref: 23] [Cited by in F6Publishing: 10] [Article Influence: 5.8] [Reference Citation Analysis]
13 Vaught AJ, Gavriilaki E, Hueppchen N, Blakemore K, Yuan X, Seifert SM, York S, Brodsky RA. Direct evidence of complement activation in HELLP syndrome: A link to atypical hemolytic uremic syndrome. Exp Hematol 2016;44:390-8. [PMID: 26921648 DOI: 10.1016/j.exphem.2016.01.005] [Cited by in Crossref: 57] [Cited by in F6Publishing: 49] [Article Influence: 9.5] [Reference Citation Analysis]
14 Kurtoğllu AU, Koçtekin B, Kurtoğlu E, Yildiz M. The effect of splenectomy on complement regulatory proteins in erythrocytes in β-thalassemia major. Arch Med Sci 2019;15:191-5. [PMID: 30697270 DOI: 10.5114/aoms.2018.81036] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
15 Lima M. Laboratory studies for paroxysmal nocturnal hemoglobinuria, with emphasis on flow cytometry. Pract Lab Med 2020;20:e00158. [PMID: 32195308 DOI: 10.1016/j.plabm.2020.e00158] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
16 Cook EM, Lindorfer MA, van der Horst H, Oostindie S, Beurskens FJ, Schuurman J, Zent CS, Burack R, Parren PW, Taylor RP. Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions. J Immunol 2016;197:1762-75. [PMID: 27474078 DOI: 10.4049/jimmunol.1600648] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 5.8] [Reference Citation Analysis]
17 Mota S, Filipe C, Almeida AL. Atypical hemolytic uremic syndrome: An unusual postoperative complication. Rev Esp Anestesiol Reanim (Engl Ed) 2018;65:351-5. [PMID: 29426622 DOI: 10.1016/j.redar.2017.12.014] [Reference Citation Analysis]
18 Michel M, Jäger U. Autoimmune Hemolytic Anemia. Hematology. Elsevier; 2018. pp. 648-662.e1. [DOI: 10.1016/b978-0-323-35762-3.00046-9] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
19 Barnum SR. Complement: A primer for the coming therapeutic revolution. Pharmacol Ther 2017;172:63-72. [PMID: 27914981 DOI: 10.1016/j.pharmthera.2016.11.014] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 6.0] [Reference Citation Analysis]
20 Kurtoǧllu AU, Koçtekin B, Kurtoǧlu E, Yildiz M, Bozkurt S. Expression of CD55, CD59, and CD35 on red blood cells of β-thalassaemia patients. Cent Eur J Immunol 2017;42:78-84. [PMID: 28680334 DOI: 10.5114/ceji.2017.67321] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
21 Broome CM, Cunningham JM, Mullins M, Jiang X, Bylsma LC, Fryzek JP, Rosenthal A. Increased risk of thrombotic events in cold agglutinin disease: A 10-year retrospective analysis. Res Pract Thromb Haemost 2020;4:628-35. [PMID: 32548562 DOI: 10.1002/rth2.12333] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
22 Dower J, Dima D, Sieker J, Pilichowska M, Varga C. Eculizumab-induced late erythroid maturation arrest: a case report. Br J Haematol 2020;191:120-2. [PMID: 32671821 DOI: 10.1111/bjh.16936] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Scordo M, Giralt S. Compliments to complement blockade for TA-TMA. Blood 2020;135:981-3. [PMID: 32219351 DOI: 10.1182/blood.2020005040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Yang CY, Phillips JG, Stuckey JA, Bai L, Sun H, Delproposto J, Brown WC, Chinnaswamy K. Buried Hydrogen Bond Interactions Contribute to the High Potency of Complement Factor D Inhibitors. ACS Med Chem Lett 2016;7:1092-6. [PMID: 27994744 DOI: 10.1021/acsmedchemlett.6b00299] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
25 Imus PH, Tsai HL, DeZern AE, Jerde K, Swinnen LJ, Bolaños-Meade J, Luznik L, Fuchs EJ, Wagner-Johnston N, Huff CA, Gladstone DE, Ambinder RF, Gocke CB, Ali SA, Borrello IM, Varadhan R, Brodsky R, Jones RJ. Thrombotic Microangiopathy after Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis. Biol Blood Marrow Transplant 2020;26:2306-10. [PMID: 32961372 DOI: 10.1016/j.bbmt.2020.09.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
26 Keshari RS, Popescu NI, Silasi R, Regmi G, Lupu C, Simmons JH, Ricardo A, Coggeshall KM, Lupu F. Complement C5 inhibition protects against hemolytic anemia and acute kidney injury in anthrax peptidoglycan-induced sepsis in baboons. Proc Natl Acad Sci U S A 2021;118:e2104347118. [PMID: 34507997 DOI: 10.1073/pnas.2104347118] [Reference Citation Analysis]
27 Yui JC, Brodsky RA. Updates in the Management of Warm Autoimmune Hemolytic Anemia. Hematology/Oncology Clinics of North America 2022. [DOI: 10.1016/j.hoc.2021.11.005] [Reference Citation Analysis]
28 Yao X, Verkman AS. Marked central nervous system pathology in CD59 knockout rats following passive transfer of Neuromyelitis optica immunoglobulin G. Acta Neuropathol Commun 2017;5:15. [PMID: 28212662 DOI: 10.1186/s40478-017-0417-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
29 Jacobsen B, Larouche D, Rochette-Drouin O, Ploug M, Germain L. Expression of C4.4A in an In Vitro Human Tissue-Engineered Skin Model. Biomed Res Int 2017;2017:2403072. [PMID: 29075641 DOI: 10.1155/2017/2403072] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
30 Leinøe E, Nielsen OJ, Jønson L, Rossing M. Whole-exome sequencing of a patient with severe and complex hemostatic abnormalities reveals a possible contributing frameshift mutation in C3AR1. Cold Spring Harb Mol Case Stud 2016;2:a000828. [PMID: 27551680 DOI: 10.1101/mcs.a000828] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
31 Douxfils J, Favresse J, Dogné JM, Lecompte T, Susen S, Cordonnier C, Lebreton A, Gosselin R, Sié P, Pernod G, Gruel Y, Nguyen P, Vayne C, Mullier F. Hypotheses behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination. Thromb Res 2021;203:163-71. [PMID: 34029848 DOI: 10.1016/j.thromres.2021.05.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
32 Petri M. Improvements in diagnosis and risk assessment of primary and secondary antiphospholipid syndrome. Hematology Am Soc Hematol Educ Program 2019;2019:415-20. [PMID: 31808834 DOI: 10.1182/hematology.2019000046] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
33 Liu X, Lieberman J. Knocking 'em Dead: Pore-Forming Proteins in Immune Defense. Annu Rev Immunol 2020;38:455-85. [PMID: 32004099 DOI: 10.1146/annurev-immunol-111319-023800] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 11.0] [Reference Citation Analysis]
34 Horiuchi T, Tsukamoto H. Complement-targeted therapy: development of C5- and C5a-targeted inhibition. Inflamm Regen 2016;36:11. [PMID: 29259684 DOI: 10.1186/s41232-016-0013-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 4.2] [Reference Citation Analysis]
35 Pretini V, Koenen MH, Kaestner L, Fens MHAM, Schiffelers RM, Bartels M, Van Wijk R. Red Blood Cells: Chasing Interactions. Front Physiol 2019;10:945. [PMID: 31417415 DOI: 10.3389/fphys.2019.00945] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 9.7] [Reference Citation Analysis]
36 Tiede A, Sachs UJ, Czwalinna A, Werwitzke S, Bikker R, Krauss JK, Donnerstag F, Weißenborn K, Höglinger G, Maasoumy B, Wedemeyer H, Ganser A. Prothrombotic immune thrombocytopenia after COVID-19 vaccination. Blood 2021;138:350-3. [PMID: 34323939 DOI: 10.1182/blood.2021011958] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 22.0] [Reference Citation Analysis]
37 Goggs R, Behling-Kelly E. C1 inhibitor in canine intravascular hemolysis (C1INCH): study protocol for a randomized controlled trial. BMC Vet Res 2019;15:475. [PMID: 31888626 DOI: 10.1186/s12917-019-2220-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
38 Kang E, Yoo SH, Oh D, Joo KW, Kim YS, Yoon SS, Kim I, Park S, Lee H, Koh Y. Clinical dissection of thrombotic microangiopathy. Ann Hematol 2017;96:1715-26. [PMID: 28752391 DOI: 10.1007/s00277-017-3063-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
39 Brady TM, Pruette C, Loeffler LF, Weidemann D, Strouse JJ, Gavriilaki E, Brodsky RA. Typical Hus: Evidence of Acute Phase Complement Activation from a Daycare Outbreak. J Clin Exp Nephrol 2016;1:11. [PMID: 27413789 DOI: 10.21767/2472-5056.100011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
40 Barbour T, Scully M, Ariceta G, Cataland S, Garlo K, Heyne N, Luque Y, Menne J, Miyakawa Y, Yoon SS, Kavanagh D; 311 Study Group Members. Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults. Kidney Int Rep 2021;6:1603-13. [PMID: 34169200 DOI: 10.1016/j.ekir.2021.03.884] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Yuan X, Li Z, Baines AC, Gavriilaki E, Ye Z, Wen Z, Braunstein EM, Biesecker LG, Cheng L, Dong X, Brodsky RA. A hypomorphic PIGA gene mutation causes severe defects in neuron development and susceptibility to complement-mediated toxicity in a human iPSC model. PLoS One 2017;12:e0174074. [PMID: 28441409 DOI: 10.1371/journal.pone.0174074] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
42 Zhou M, Yuan F. Hypocomplementemia in Primary Sjogren's Syndrome: A Retrospective Study of 120 Treatment-Naive Chinese Patients. Int J Gen Med 2022;15:359-66. [PMID: 35035231 DOI: 10.2147/IJGM.S346188] [Reference Citation Analysis]
43 Jäger U, D'Sa S, Schörgenhofer C, Bartko J, Derhaschnig U, Sillaber C, Jilma-Stohlawetz P, Fillitz M, Schenk T, Patou G, Panicker S, Parry GC, Gilbert JC, Jilma B. Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial. Blood 2019;133:893-901. [PMID: 30559259 DOI: 10.1182/blood-2018-06-856930] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 9.8] [Reference Citation Analysis]
44 Yuan X, Gavriilaki E, Thanassi JA, Yang G, Baines AC, Podos SD, Huang Y, Huang M, Brodsky RA. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Haematologica 2017;102:466-75. [PMID: 27810992 DOI: 10.3324/haematol.2016.153312] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 7.5] [Reference Citation Analysis]
45 Elieh Ali Komi D, Shafaghat F, Kovanen PT, Meri S. Mast cells and complement system: Ancient interactions between components of innate immunity. Allergy 2020;75:2818-28. [PMID: 32446274 DOI: 10.1111/all.14413] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
46 Long Z, Du Y, Li H, Han B. CR1 gene polymorphisms in Chinese patients with paroxysmal nocturnal hemoglobinuria. Gene 2018;659:149-54. [DOI: 10.1016/j.gene.2018.03.037] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
47 Yuan Z, Wei Y, Chen X, He S, Cai K, Zhong M, Huang H, Tong X, Liu Z, Yang X. Anti-JMH alloantibody in inherited JMH-negative patients leads to immunogenic destruction of JMH-positive RBCs. Clin Exp Immunol 2021;205:182-97. [PMID: 34021913 DOI: 10.1111/cei.13622] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
48 Gavriilaki E, Anagnostopoulos A, Mastellos DC. Complement in Thrombotic Microangiopathies: Unraveling Ariadne's Thread Into the Labyrinth of Complement Therapeutics. Front Immunol 2019;10:337. [PMID: 30891033 DOI: 10.3389/fimmu.2019.00337] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 11.7] [Reference Citation Analysis]
49 Pandey P, Anani WQ, Gottschall JL, Denomme GA. Potential impact of complement regulator deficiencies on hemolytic reactions due to minor ABO-mismatched transfusions. Blood Adv 2017;1:1977-82. [PMID: 29296844 DOI: 10.1182/bloodadvances.2017008805] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
50 Gelbenegger G, Schoergenhofer C, Derhaschnig U, Buchtele N, Sillaber C, Fillitz M, Schenk TM, D'Sa S, Cartwright R, Gilbert JC, Jilma B, Jaeger U. Inhibition of complement C1s in patients with cold agglutinin disease: lessons learned from a named patient program. Blood Adv 2020;4:997-1005. [PMID: 32176765 DOI: 10.1182/bloodadvances.2019001321] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
51 Brodsky RA. Eculizumab: another breakthrough. Blood 2017;129:922-3. [PMID: 28232621 DOI: 10.1182/blood-2017-01-760496] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
52 Stefanovic V. The Extended Use of Eculizumab in Pregnancy and Complement Activation⁻Associated Diseases Affecting Maternal, Fetal and Neonatal Kidneys-The Future Is Now? J Clin Med 2019;8:E407. [PMID: 30909646 DOI: 10.3390/jcm8030407] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
53 McDonald L, Brodie R, Murphy K, Wright P, Webster R, Fitzgerald J. Piperacillin-tazobactam drug-induced immune haemolysis in a case of paroxysmal nocturnal haemoglobinuria. Transfus Med 2019;29:138-40. [PMID: 30916843 DOI: 10.1111/tme.12592] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]